SciClone Pharmaceuticals Inc
Cecile Pan is an accomplished finance professional with extensive experience in leadership roles. Currently serving as the VP of Finance and CFO at SciClone Pharmaceuticals since November 2018, Cecile has demonstrated expertise in managing financial strategies and operations. Prior to this role, Cecile was a Partner at PwC from July 2013 to November 2018, where responsibilities included providing high-level financial consulting and advisory services.
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.